A.I. Learns to Write in DNA
Scientists prompted A.I. to design and create new viruses for the first time, a milestone for medicine that also raises new biosecurity concerns.
Anthropic closed a $65 billion Series H this week at a $965 billion post-money valuation, officially passing OpenAI's last known mark of $730 billion to claim the top spot among private AI companies. It is the kind of number that would have seemed fictional two years ago. Now it is a fundraising record and a signal that the AI investment cycle is nowhere near cooling off.
The round is widely read as Anthropic's final lap before an IPO. Claude's aggressive enterprise penetration — particularly in software development, where it has become the preferred coding assistant for a growing list of Fortune 500 teams — appears to be the primary argument that won over investors. Revenue growth, not just hype, is what pushed the valuation past OpenAI.
The shift in the AI pecking order is real and consequential. For years OpenAI had the biggest brand, the biggest model, and the biggest check. Now it has a rival with a credible claim to all three — and a safety-first positioning that plays well with the regulators circling the industry. The race just got a second horse.
All comments are reviewed before appearing. Keep it respectful.
Scientists prompted A.I. to design and create new viruses for the first time, a milestone for medicine that also raises new biosecurity concerns.
The Trump administration has no idea on how to handle open-source and open-weight AI models from China.
Google is consolidating AI leadership in California but the reorganization is pushing out the engineers who built its AI division